Development status of pharmaceutical industry

(1) How big is the pharmaceutical market?

Generally speaking, the pharmaceutical industry can be divided into pharmaceutical manufacturing, pharmaceutical circulation and medical services, and each sector can be further subdivided. For example, pharmaceutical manufacturing includes drugs (chemicals, traditional Chinese medicine and biological drugs) and devices, pharmaceutical circulation includes drug distribution and retail pharmacies, and medical services include chain medical institutions and CRO (pharmaceutical R&D contract outsourcing service organization).

According to the data of the National Bureau of Statistics, in 2020, the main business income of domestic pharmaceutical manufacturing enterprises above designated size increased by 4.5 1% year-on-year, and the total profit increased by 12.8 1% year-on-year. Although the income growth rate of pharmaceutical and biological industries will slow down (65,438+08%) due to the epidemic in 2020, the growth rate of total profits will increase by 2.7% compared with 2065,438+09. On the whole, China's pharmaceutical market has become the second largest pharmaceutical market in the world after the United States, and it still maintains an income growth rate (2.3%) that is close to twice the GDP growth rate.

(2) The future development can still be expected.

With the deepening of medical reform after 20 14, the "golden decade" of the pharmaceutical industry has become a thing of the past, but overall, the industry still has outstanding growth advantages.

Under the background of the "three-medical linkage" new medical reform, medical insurance fee control has become the new normal, and the pattern of industries and enterprises has gradually changed. The goal of medical insurance reform is to control the cost and quantity procurement of auxiliary drugs and traditional Chinese medicine injections (the state has agreed on the minimum purchase quantity of generic drugs that have passed the consistency evaluation, which will be supplied by the manufacturer with the lowest quotation), which has laid a good foundation for the vigorous development of innovative drug products.

In addition, affected by the epidemic situation in COVID-19, perfecting the system and filling the shortcomings of public health will become one of the development directions of the industry. In the long run, medicine will become an important part of the "new infrastructure", and the related pharmaceutical industry chain is also expected to usher in greater long-term stable investment and more construction opportunities.